(Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and ...

For leaders in business, failing to learn the lessons of a crisis can be disastrous. For leaders in government, when millions ...

The mRNA platform enabled scientists to begin work on a vaccine within days of the publication of COVID-19’s genetic sequence. Clinical trials for an mRNA vaccine began weeks la ...

"I am saddened and outraged that more citizens are not tuning into this war against scientific health research in the United ...

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

Single-cell proteomics with RNA sequencing uncover hidden gene expression dynamics in stem cell differentiation.

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Studying the process of brain formation illuminates just how much of development is a series of tiny miracles. Only a few ...

An announcement from Ionis Pharmaceuticals ( (IONS) ) is now available. On August 21, 2025, Ionis Pharmaceuticals announced that the FDA approved DAWNZERA™ (donidalorsen) for preventing hereditary ...

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

In the past decade, there has been significant interest in studying the expression of our genetic code down to the level of ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.